SM
KERX

Sabby Management’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

Sabby Management’s Portfolio KERX Stock Details KERX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-250
Closed -$354 – 339
2014
Q4 		$354 Hold
250
– – 0.01% 199
2014
Q3 		$344 Buy
+250
New +$3.83K 0.01% 201
2014
Q1 		– Sell
-10,147
Closed -$13.1M – 293
2013
Q4 		$13.1M Buy
10,147
+9,598
+1,748% +$115K 0.84% 29
2013
Q3 		$554K Sell
549
-365
-40% -$3.25K 0.04% 151
2013
Q2 		$683K Buy
+914
New +$7.14K 0.05% 135

Other funds holding KERX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Sabby Management's KERX Position: Q2 2015 in Review

Sabby Management sold out of Keryx Biopharmaceuticals Inc (KERX) in Q2 2015, closing a stake of 14,758 shares — an estimated $158K sold.

Sabby Management first reported a position in KERX in Q2 2013 and held it in 4 quarters. The position peaked at $5.57M in Q2 2013. 153 funds tracked by Wall St. Rank hold KERX as of Q2 2015.

  • Sabby Management reported no remaining Keryx Biopharmaceuticals Inc position as of Q2 2015 after selling out during the quarter.
  • Sabby Management sold 14,758 Keryx Biopharmaceuticals Inc shares in Q2 2015, an estimated $158K.
  • Sabby Management first reported a position in Keryx Biopharmaceuticals Inc in Q2 2013 and held it in 4 quarters.
  • Sabby Management's Keryx Biopharmaceuticals Inc position peaked at $5.57M in Q2 2013.
  • 153 funds tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q2 2015.

Based on Sabby Management's 13F filing for Q2 2015, filed 14 Aug 2015.